A PHASE-II STUDY OF TAMOXIFEN COMBINED WITH CISPLATIN-INTERLEUKIN-2 AND ALPHA-INTERFERON IN METASTATIC MELANOMA

被引：5
|
作者：
ANTOINE, EC
RIXE, O
VUILLEMIN, E
BENHAMMOUDA, A
BOREL, C
GHIRONZI, GC
MULARONI, E
FRANKS, C
AUCLERC, G
SOUBRANE, C
BANZET, P
WEIL, M
KHAYAT, D
机构：
[1] HOP ST LOUIS,DEPT SURG,PARIS,FRANCE
[2] ROCHE FRANCE LAB,NEUILLY SUR SEINE,FRANCE
[3] EUROCETUS BV,1105 BJ AMSTERDAM,NETHERLANDS
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1995年 / 18卷 / 05期
关键词：
TAMOXIFEN; CISPLATIN; IMMUNOTHERAPY; MELANOMA;
D O I：
10.1097/00000421-199510000-00012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tamoxifen (TAM) has been reported to enhance cisplatin (CDDP) cytotoxicity in experimental and clinical melanoma studies. Based on our previous experience with sequential cisplatin-interleukin-2 (IL2)-interferon (IFN), we performed a phase II study of TAM combined with our original CDDP-IL2-IFN regimen in 22 pretreated metastatic melanoma patients. With a 41% response rate (95% Cl, 21-61) we confirmed the interesting antitumor activity of CDDP-IL2-IFN combination; however, TAM enhanced neither the response rate nor the duration of response, but appeared to induce significantly more myelotoxicity, as compared to our previous results with CDDP-IL2-IFN alone. Whereas mechanisms by which TAM may modulate CDDP cytotoxicity in melanoma tumors remain unknown, the exact place of TAM, if any, and its safety in chemotherapeutic or chemoimmunotherapeutic combinations require further investigations.
引用
收藏
页码：421 / 424
页数：4
相关论文
共 50 条
  • [41] Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial
    Kim A. Margolin
    P. Y. Liu
    Joseph M. Unger
    William S. Fletcher
    Lawrence E. Flaherty
    Walter J. Urba
    Evan M. Hersh
    Laura E. Hutchins
    Jeffrey A. Sosman
    John W. Smith
    Geoffrey R. Weiss
    Vernon K. Sondak
    Journal of Cancer Research and Clinical Oncology, 1999, 125 : 292 - 296
  • [42] Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma:: a Southwest Oncology Group trial
    Margolin, KA
    Liu, PY
    Unger, JM
    Fletcher, WS
    Flaherty, LE
    Urba, WJ
    Hersh, EM
    Hutchins, LE
    Sosman, JA
    Smith, JW
    Weiss, GR
    Sondak, VK
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (05) : 292 - 296
  • [43] Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
    R Hoffmann
    I Müller
    K Neuber
    S Lassmann
    J Buer
    M Probst
    K Oevermann
    A Franzke
    H Kirchner
    A Ganser
    J Atzpodien
    British Journal of Cancer, 1998, 78 : 1076 - 1080
  • [44] Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
    Hoffmann, R
    Müller, I
    Neuber, K
    Lassmann, S
    Buer, J
    Probst, M
    Oevermann, K
    Franzke, A
    Kirchner, H
    Ganser, A
    Atzpodien, J
    BRITISH JOURNAL OF CANCER, 1998, 78 (08) : 1076 - 1080
  • [45] A PHASE-II STUDY OF COMBINED ADMINISTRATION OF DACARBAZINE AND CARBOPLATIN WITH HOME THERAPY OF RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2A IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA
    RON, IG
    MORDISH, Y
    EISENTHAL, A
    SKORNICK, Y
    INBAR, MJ
    CHAITCHIK, S
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 38 (06) : 379 - 384
  • [46] PHASE-II TRIAL OF LYMPHOBLASTOID INTERFERON IN METASTATIC MALIGNANT-MELANOMA
    GOLDBERG, RM
    AYOOB, M
    SILGALS, R
    AHLGREN, JD
    NEEFE, JR
    CANCER TREATMENT REPORTS, 1985, 69 (7-8): : 813 - 816
  • [47] A PHASE-II STUDY OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN HEAD AND NECK-CANCER
    SCHANTZ, SP
    DIMERY, I
    LIPPMAN, SM
    CLAYMAN, GL
    PELLEGRINO, C
    MORICE, R
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (03) : 217 - 223
  • [48] Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α2a and tamoxifen in metastatic melanoma
    Sertoli, MR
    Queirolo, P
    Bajetta, E
    DelVecchio, M
    Comella, G
    Barduagni, L
    Bernengo, MG
    Vecchio, S
    Criscuolo, D
    Bufalino, R
    Morabito, A
    Cascinelli, N
    MELANOMA RESEARCH, 1999, 9 (05) : 503 - 509
  • [49] INTERFERON-BETA, RETINOIDS, AND TAMOXIFEN IN THE TREATMENT OF METASTATIC BREAST-CANCER - A PHASE-II STUDY
    RECCHIA, F
    SICA, G
    DEFILIPPIS, S
    DISCEPOLI, S
    REA, S
    TORCHIO, P
    FRATI, L
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1995, 15 (07): : 605 - 610
  • [50] Subcutaneous interleukin-2 and interferon-α plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma:: a phase II study
    Schmidt, H
    Geertsen, PF
    Fode, K
    Rytter, C
    Bastholt, L
    von der Maase, H
    MELANOMA RESEARCH, 2000, 10 (01) : 66 - 77
12345